Pemphigus mouse model as a tool to evaluate various immunosuppressive therapies

Experimental Dermatology

Volumn 18, Issue 3, 2009, Pages 252-260

  Takae, Yujiro ^a   Nishikawa, Takeji ^a   Amagai, Masayuki ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Autoantibody; Evaluation; Immunosuppressive therapy; Mouse model; Pemphigus vulgaris

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DESMOGLEIN 3 ANTIBODY; DEXAMETHASONE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; TACROLIMUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL ANIMAL; FEMALE; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MALE; MOUSE; NONHUMAN; PEMPHIGUS VULGARIS; PHENOTYPE; WEIGHT REDUCTION;

ANIMALS; AZATHIOPRINE; BODY WEIGHT; CYCLOPHOSPHAMIDE; CYCLOSPORINE; DESMOGLEIN 3; DEXAMETHASONE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEMPHIGUS; PHENOTYPE; TACROLIMUS;

EID: 64549114217     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00776.x     Document Type: Article

References (36)

1. Amagai M, Ahmed A R, Kitajima Y et al. Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just "witnesses of disease"? Exp Dermatol 2006: 15: 815-831.
2. Ishii K, Amagai M, Hall R P et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997: 159: 2010-2017.
3. Cheng S W, Kobayashi M, Kinoshita-Kuroda K, Tanikawa A, Amagai M, Nishikawa T. Monitoring disease activity in pemphigus with enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3. Br J Dermatol 2002: 147: 261-265.
4. Amagai M, Komai A, Hashimoto T et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999: 140: 351-357.
5. Sekiguchi M, Futei Y, Fujii Y, Iwasaki T, Nishikawa T, Amagai M. Dominant autoimmune epitopes recognized by pemphigus antibodies map to the N-terminal adhesive region of desmogleins. J Immunol 2001: 167: 5439-5448.
6. Muller R, Svoboda V, Wenzel E, Muller H H, Hertl M. IgG against extracellular subdomains of desmoglein 3 relates to clinical phenotype of pemphigus vulgaris. Exp Dermatol 2008: 17: 35-43.
7. Amagai M, Tsunoda K, Suzuki H, Nishifuji K, Koyasu S, Nishikawa T. Use of autoantigen-knockout mice in developing an active autoimmune disease model for pemphigus. J Clin Invest 2000: 105: 625-631.
8. Amagai M. Pemphigus as a paradigm of autoimmunity and cell adhesion. Keio J Med 2002: 51: 133-139.
9. Aoki-Ota M, Tsunoda K, Ota T et al. A mouse model of pemphigus vulgaris by adoptive transfer of naive splenocytes from desmoglein 3 knockout mice. Br J Dermatol 2004: 151: 346-354.
10. Ohyama M, Amagai M, Tsunoda K et al. Immunologic and histopathologic characterization of an active disease mouse model for pemphigus vulgaris. J Invest Dermatol 2002: 118: 199-204.
11. Sakic B, Szechtman H, Denburg S D, Denburg J A. Immunosuppressive treatment prevents behavioral deficit in autoimmune MRL-lpr mice. Physiol Behav 1995: 58: 797-802.
12. Shiraki M, Fujiwara M, Tomura S. Long term administration of cyclophosphamide in MRL/1 mice. I. The effects on the development of immunological abnormalities and lupus nephritis. Clin Exp Immunol 1984: 55: 333-339.
13. Casey T P. Azathioprine administration to NZB X NZW hybrid mice with lupus nephritis: Beneficial effect complicated by development of malignant lymphomas. N Z Med J 1973: 79: 290-295.
14. Jabs D A, Lee B, Burek C L, Saboori A M, Prendergast R A. Cyclosporine therapy suppresses ocular and lacrimal gland disease in MRL/Mp-lpr/lpr mice. Invest Ophthalmol Vis Sci 1996: 37: 377-383.
15. Gold B G, Voda J, Yu X, McKeon G, Bourdette D N. FK506 and a nonimmunosuppressant derivative reduce axonal and myelin damage in experimental autoimmune encephalomyelitis: Neuroimmunophilin ligand-mediated neuroprotection in a model of multiple sclerosis. J Neurosci Res 2004: 77: 367-377.
16. Herrmann P, Schreier M H, Borel J F. Suppression of DTH mediated by cloned helper T cells with ciclosporin and dexamethasone. Agents Actions 1986: 19: 280-281.
17. Trune D R, Wobig R J, Kempton J B, Hefeneider S H. Steroid treatment improves cochlear function in the MRL.MpJ-Fas(lpr) autoimmune mouse. Hear Res 1999: 137: 160-166.
18. Trune D R, Wobig R J, Kempton J B, Hefeneider S H. Steroid treatment in young MRL.MpJ-Fas(lpr) autoimmune mice prevents cochlear dysfunction. Hear Res 1999: 137: 167-173.
19. Bartlett R R, Popovic S, Raiss R X. Development of autoimmunity in MRL/ lpr mice and the effects of drugs on this murine disease. Scand J Rheumatol Suppl 1988: 75: 290-299.
20. Austin H A III, Patel A D, Cadena C A, Boumpas D T, Balow J E. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus. J Rheumatol 1997: 24: 61-68.
21. Morris A D, Esterly J, Chase G, Sharp G C. Cyclophosphamide protection in NZB/NZW disease. Mechanisms and therapeutic regimens. Arthritis Rheum 1976: 19: 49-55.
22. Lando Z, Teitelbaum D, Arnon R. Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 1979: 123: 2156-2160.
23. Amagai M, Klaus-Kovtun V, Stanley J R. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991: 67: 869-877.
24. Amagai M, Karpati S, Prussick R, Klaus-Kovtun V, Stanley J R. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992: 90: 919-926.
25. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994: 94: 59-67.
26. Dedrick R, Bischoff K B, Zaharko D S. Interspecies correlation of plasma concentration history of methotrexate (NSC-740). Cancer Chemother Rep 1970: 54: 95-101.
27. Nguyen V T, Arredondo J, Chernyavsky A I, Kitajima Y, Pittelkow M, Grando S A. Pemphigus vulgaris IgG and methylprednisolone exhibit reciprocal effects on keratinocytes. J Biol Chem 2004: 279: 2135-2146.
28. Jameson S C. Maintaining the norm: T-cell homeostasis. Nat Rev Immunol 2002: 2: 547-556.
29. Stockinger B, Barthlott T, Kassiotis G. The concept of space and competition in immune regulation. Immunology 2004: 111: 241-247.
30. Stockinger B, Kassiotis G, Bourgeois C. Homeostasis and T cell regulation. Curr Opin Immunol 2004: 16: 775-779.
31. Pandya A G, Sontheimer R D. Treatment of pemphigus vulgaris with pulse intravenous cyclophosphamide. Arch Dermatol 1992: 128: 1626-1630.
32. Fleischli M E, Valek R H, Pandya A G. Pulse intravenous cyclophosphamide therapy in pemphigus. Arch Dermatol 1999: 135: 57-61.
33. Roenigk H H Jr, Deodhar S. Pemphigus treatment with azathioprine. Clinical and immunologic correlation. Arch Dermatol 1973: 107: 353-357.
34. Lapidoth M, David M, Ben-Amitai D, Katzenelson V, Lustig S, Sandbank M. The efficacy of combined treatment with prednisone and cyclosporine in patients with pemphigus: Preliminary study. J Am Acad Dermatol 1994: 30: 752-757.
35. Barthelemy H, Frappaz A, Cambazard F et al. Treatment of nine cases of pemphigus vulgaris with cyclosporine. J Am Acad Dermatol 1988: 18: 1262-1266.
36. Gach J E, Ilchyshyn A. Beneficial effects of topical tacrolimus on recalcitrant erosions of pemphigus vulgaris. Clin Exp Dermatol 2004: 29: 271-272.